MONOPHARMA

Mono Pharmacare Share Price

 

 

Start SIP in MONOPHARMA

Start SIP
Mono Pharmacare live price: ₹11.6. It opened at ₹12 vs previous close ₹11; intraday high/low: ₹12/₹12. The 50 & 200 DMA stand at ₹13.78/₹22.05.

Mono Pharmacare Performance

  • Low
  • ₹12
  • High
  • ₹12
  • 52 Week Low
  • ₹9
  • 52 Week High
  • ₹29
  • Open Price₹12
  • Previous Close₹11
  • Volume84,000
  • 50 DMA₹13.78
  • 100 DMA₹16.97
  • 200 DMA₹22.05

Investment Returns

  • Over 1 Month -2.52%
  • Over 3 Month -31.96%
  • Over 6 Month -52.56%
  • Over 1 Year -57.43%

Smart Investing Starts Here Start SIP with Mono Pharmacare for Steady Growth!

Invest Now

Mono Pharmacare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 6.6
  • PEG Ratio
  • -
  • Market Cap Cr
  • 21
  • P/B Ratio
  • 0.7
  • Average True Range
  • 0.6
  • EPS
  • 1.75
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.61
  • RSI
  • 44.74
  • MFI
  • 63.5

Mono Pharmacare Financials

Mono Pharmacare Technicals

EMA & SMA

Current Price
₹11.60
+ 0.45 (4.04%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹11.83
  • 50 Day
  • ₹13.78
  • 100 Day
  • ₹16.97
  • 200 Day
  • ₹22.05

Resistance and Support

11.62 Pivot Speed
  • R3 11.68
  • R2 11.67
  • R1 11.63
  • S1 11.58
  • S2 11.57
  • S3 11.53

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Mono Pharmacare Ltd has an operating revenue of Rs. 356.98 Cr. on a trailing 12-month basis. An annual revenue growth of 38% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 9% is fair but needs improvement. The company has a debt to equity of 83%, which is bit higher. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 4 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D- which indicates heavy supply, Group Rank of 160 indicates it belongs to a poor industry group of Medical-Whlsle Drg/Suppl and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Mono Pharmacare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-29 Quarterly Results & Others To consider other business matters (Revised)
2025-08-26 Others To consider other business matters
2025-05-30 Audited Results & Others (Revised) To consider other business matters.
2025-04-11 Others To consider other business matters (Revised)
2025-02-10 Others To consider other business matters

Mono Pharmacare F&O

Mono Pharmacare Shareholding Pattern

56.72%
34.47%
8.81%

About Mono Pharmacare

  • NSE Symbol
  • MONOPHARMA
  • BSE Symbol
  • Managing Director
  • Mr. Panilam Lakhatariya
  • ISIN
  • INE0OIP01012

Similar Stocks to Mono Pharmacare

Mono Pharmacare FAQs

Mono Pharmacare share price is ₹11 As on 16 March, 2026 | 16:40

The Market Cap of Mono Pharmacare is ₹20.5 Cr As on 16 March, 2026 | 16:40

The P/E ratio of Mono Pharmacare is 6.6 As on 16 March, 2026 | 16:40

The PB ratio of Mono Pharmacare is 0.7 As on 16 March, 2026 | 16:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23